Accretion Pharma reported strong FY26 financials: Revenue up 56.21% to 89.63 Cr, PAT up 42.30% to 9.67 Cr.

H2 FY26 revenue grew 18.24% to 45.89 Cr.

Growth was driven by volume, product mix, and export expansion into Africa, LatAm, and Southeast Asia.

Margins were impacted by input costs and strategic investments.